Read more" />

Pfizer begins mid-stage trial for new vaccine targeting Omicron subvariant – National

Pfizer Inc and its German accomplice BioNTech SE stated on Wednesday they’d began a mid-stage research of a modified COVID-19 vaccine which targets each the unique in addition to the BA.2 Omicron subvariant.

Pfizer stated the vaccine is in an preliminary proof-of-concept research to assemble extra information.

Learn extra:

COVID vaccination clinics to be held at Caribbean Carnival, other summer events in Toronto

Collectively, the BA.4 and BA.5 subvariants are estimated to make up practically 95% of the circulating coronavirus variants in the US for the week ended July 23.

The U.S. Meals and Drug Administration final month requested vaccine producers to focus on BA.4 and BA.5, the 2 at the moment dominant Omicron subvariants, for a possible fall season booster dose.

Leave a Comment